Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition.

Brain Research
S K Kidd, Jay S Schneider

Abstract

Although the pathophysiological processes involved in dopamine (DA) neuron degeneration in Parkinson's disease (PD) are not completely known, apoptotic cell death has been suggested to be involved and can be modeled in DAergic cell lines using the mitochondrial toxin 1-methyl-4-phenylpyridinium (MPP(+)). Recently, it has been suggested that histone deacetylase inhibitors (HDACIs) may reduce apoptotic cell death in various model systems. However, their utility in interfering with DA cell death remains unclear. The HDACIs sodium butyrate (NaB), valproate (VPA) and suberoylanilide hydroxamic acid (SAHA) were tested for their ability to prevent MPP(+)-mediated cytotoxicity in human derived SK-N-SH and rat derived MES 23.5 cells. All three HDACIs at least partially prevented MPP(+)-mediated apoptotic cell death. The protective effects of these HDACIs coincided with significant increases in histone acetylation. These results suggest that HDACIs may be potentially neuroprotective against DA cell death and should be explored further in animal models of PD.

References

Mar 18, 2003·Proceedings of the National Academy of Sciences of the United States of America·Hoon RyuAlpaslan Deodoglu
Dec 6, 2003·The EMBO Journal·Caroline RouauxAnne-Laurence Boutillier
Sep 2, 2006·Biological Psychiatry·Frederick A SchroederSchahram Akbarian
Mar 7, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Yan LengDe-Maw Chuang
Jul 10, 2008·The International Journal of Neuropsychopharmacology·Xuefei WuJau-Shyong Hong
Oct 2, 2008·Nature Reviews. Drug Discovery·Aleksey G Kazantsev, Leslie M Thompson
Oct 20, 2009·Neuroscience Letters·Yong WangXiaomin Wang

❮ Previous
Next ❯

Citations

Sep 14, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Navneet Ammal KaideryBobby Thomas
May 25, 2012·TheScientificWorldJournal·Fabio Coppedè
Jan 10, 2013·Pharmacological Reviews·Chi-Tso ChiuDe-Maw Chuang
May 29, 2013·Pharmacology & Therapeutics·Ian F Harrison, David T Dexter
Feb 13, 2016·Neuroscience Letters·Megan W BourassaRajiv R Ratan
Jun 16, 2015·Neurotoxicology and Teratology·Kelly R GenskowW Michael Caudle
Jun 15, 2015·Progress in Neurobiology·Roy LardenoijeBart P F Rutten
Mar 17, 2015·Frontiers in Cellular Neuroscience·Jorge Landgrave-GómezRosalinda Guevara-Guzmán
Feb 20, 2015·Parkinson's Disease·Sorabh Sharma, Rajeev Taliyan
Jun 18, 2016·BioMed Research International·Prashant TaraleKannan Krishnamurthi
Jul 1, 2016·Acta Neuropathologica·Catherine LabbéOwen A Ross
Nov 5, 2016·Parkinsonism & Related Disorders·Marcus M UngerKarl-Herbert Schäfer
Sep 3, 2016·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Toros A DincmanScott R Whittemore
Jan 10, 2017·The International Journal of Biochemistry & Cell Biology·Adele RomanoAnna Maria Giudetti
Feb 15, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Erin M Hill-BurnsHaydeh Payami
Feb 25, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Mohamed ElfilSara M Schaefer
Apr 20, 2017·Psychopharmacology·Janitza L Montalvo-OrtizHongxin Dong
Aug 1, 2020·Nutritional Neuroscience·Sian EgertonCatherine Stanton
Aug 31, 2018·Journal of Neuropathology and Experimental Neurology·Malgorzata Ziemka-NaleczTeresa Zalewska
Jun 12, 2019·Metabolomics : Official Journal of the Metabolomic Society·Jacopo TroisiMarianna Amboni
Jun 20, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Hiroshi NishiwakiKinji Ohno
Jun 24, 2017·Cellular and Molecular Life Sciences : CMLS·Susan WestfallSatya Prakash
Oct 20, 2018·International Journal of Molecular Sciences·Oscar Teijido, Ramón Cacabelos
Feb 26, 2019·Frontiers in Psychiatry·Stephanie G CheungM Elizabeth Sublette
Jul 10, 2019·Frontiers in Neurology·Thaisa M Cantu-JunglesBruce R Hamaker
Oct 18, 2020·Nature Reviews. Neuroscience·Brittany D NeedhamSarkis K Mazmanian
Mar 7, 2021·Nutrients·Shirley Mei-Sin Tran, M Hasan Mohajeri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Astrocytes & Neurodegeneration

Astrocytes are important for the health and function of the central nervous system. When these cells stop functioning properly, either through gain of function or loss of homeostatic controls, neurodegenerative diseases can occur. Here is the latest research on astrocytes and neurodegeneration.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.